Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,491,078 shares, an increase of 9.2% from the January 12th total of 4,112,919 shares. Based on an average daily trading volume, of 236,822 shares, the short-interest ratio is presently 19.0 days. Approximately 2.9% of the shares of the company are short sold.
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) opened at $0.35 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $0.31 and a 1-year high of $0.85. The company has a market capitalization of $57.96, a P/E ratio of -4.86 and a beta of -0.76.
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu KCG Holdings LLC grew its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 305.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 336,414 shares of the biopharmaceutical company’s stock after buying an additional 253,471 shares during the period. Virtu KCG Holdings LLC owned about 0.21% of Navidea Biopharmaceuticals worth $172,000 as of its most recent SEC filing.
Navidea Biopharmaceuticals Company Profile
Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.